Agios Pharmaceuticals stock tumbles 25% after Novo data [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk said etavopivat demonstrated a 27% reduction in vaso-occlusive crisis events and approximately four-month delay to first vaso-occlusive crisis event on top of standard of care in patients with sickle cell disease. The data comes as Agios works with the FDA to find a path forward for its own sickle cell drug candidate, mitapivat, under an accelerated approval pathway. Agios is developing mitapivat as an experimental therapy for the same indication. Truist analyst Gregory Renza, who maintains a buy rating on Agios, commented that the "competitor trial win for Etavopivat in SCD creates separation amongst PK class candidates." Renza noted that while Agios shares could face pressure from Novo's data, "we believe the majority of the impact of the mix data has been baked into the stock at this point." The analyst added that "we come away still seeing a place for mitapivat in SCD given the high unmet need globally, and an opportunity for AGIO to leverage growing infrastruc
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Here's Why Agios Pharmaceuticals Crashed 23% Today [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Eyes Rare Disease Growth As Etavopivat Phase 3 Succeeds [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: From Sell To Buy In 90 Days, Here's What Changed My Mind [Seeking Alpha]Seeking Alpha
- Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal [Yahoo! Finance]Yahoo! Finance
- Beyond GLP-1Rs: emerging targets poised to gain share of obesity market [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- NVO's page on the SEC website